Evidence map›Paper›PMID 38022600›Full record

ArticleFrontiers in immunology2023

High maternal-fetal HLA eplet compatibility is associated with severe manifestation of preeclampsia.

Katarzyna Stefańska, Małgorzata Kurkowiak, Karolina Piekarska, Elżbieta Chruściel, Dorota Zamkowska, Joanna Jassem-Bobowicz, Przemysław Adamski, Renata Świątkowska-Stodulska, Anna Abacjew-Chmyłko, Katarzyna Leszczyńska and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Katarzyna Stefańska *Department of Gynecology and Obstetrics Medical University of Gdansk, Gdańsk, Poland.
Małgorzata Kurkowiak *International Centre for Cancer Vaccine Science (ICCVS), University of Gdańsk, Gdańsk, Poland.
Karolina PiekarskaLaboratory of Immunology and Clinical Transplantology, University Clinical Centre in Gdańsk, Gdańsk, Poland.
Elżbieta ChruścielInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdańsk, Gdańsk, Poland.
Dorota ZamkowskaDepartment of Gynecology and Obstetrics Medical University of Gdansk, Gdańsk, Poland.
Joanna Jassem-BobowiczDepartment of Neonatology, Medical University of Gdansk, Gdańsk, Poland.
Przemysław AdamskiDepartment of Gynecology and Obstetrics Medical University of Gdansk, Gdańsk, Poland.
Renata Świątkowska-StodulskaDepartment of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdańsk, Poland.
Anna Abacjew-ChmyłkoDepartment of Gynecology and Obstetrics Medical University of Gdansk, Gdańsk, Poland.
Katarzyna LeszczyńskaDepartment of Gynecology and Obstetrics Medical University of Gdansk, Gdańsk, Poland.
Maciej ZielińskiDepartment of Medical Immunology, Medical University of Gdansk, Gdańsk, Poland.
Krzysztof PreisDepartment of Gynecology and Obstetrics Medical University of Gdansk, Gdańsk, Poland.
Hanna ZielińskaLaboratory of Immunology and Clinical Transplantology, University Clinical Centre in Gdańsk, Gdańsk, Poland.
Bogusław TymoniukDepartment of Immunology and Allergy, Medical University of Łódź, Łódź, Poland.
Piotr TrzonkowskiDepartment of Medical Immunology, Medical University of Gdansk, Gdańsk, Poland.
Natalia Maria Marek-TrzonkowskaInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdańsk, Gdańsk, Poland.
Gdańsk Medical University · PLUniversity of Gdańsk · PLMedical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Preeclampsia is responsible for more than 70 000 and 500 000 maternal and fetal deaths, respectively each year. Incomplete remodelling of the spiral arteries in placenta is the most accepted theory of preeclampsia pathogenesis. However, the process is complexed with immunological background, as pregnancy resembles allograft transplantation. Fetus expresses human leukocyte antigens (HLA) inherited from both parents, thus is semiallogeneic to the maternal immune system. Therefore, induction of fetal tolerance is crucial for physiological outcome of pregnancy. Noteworthy, the immunogenicity of discordant HLA antigens is determined by functional epitopes called eplets, which are continuous and discontinuous short sequences of amino acids. This way various HLA molecules may express the same eplet and some HLA incompatibilities can be more immunogenic due to different eplet combination. Therefore, we hypothesized that maternal- fetal HLA incompatibility may be involved in the pathogenesis of gestational hypertension and its progression to preeclampsia. We also aimed to test if particular maternal-fetal eplet mismatches are more prone for induction of anti- fetal HLA antibodies in gestational hypertension and preeclampsia. Methods: High resolution next-generation sequencing of HLA-A, -B, -C, -DQB1 and -DRB1 antigens was performed in mothers and children from physiological pregnancies (12 pairs) and from pregnancies complicated with gestational hypertension (22 pairs) and preeclampsia (27 pairs). In the next step HLA eplet identification and analysis of HLA eplet incompatibilities was performed with in silico approach HLAMatchmaker algorithm. Simultaneously maternal sera were screened for anti-fetal HLA class I, class II and anti-MICA antibodies with Luminex, and data were analyzed with HLA-Fusion software. Results: We observed that high HLA-C, -B, and DQB1 maternal-fetal eplet compatibility was associated with severe preeclampsia (PE) manifestation. Both quantity and quality of HLA epletmismatches affected the severity of PE. Mismatches in HLA-B eplets: 65QIA+76ESN, 70IAO, 180E, HLA-C eplets: 193PL3, 267QE, and HLA-DRB1 eplet: 16Y were associated with a mild outcome of preeclampsia if the complication occurred. Conclusions: High HLA-C, HLA-DQB1 and HLA-B eplet compatibility between mother and child is associated with severe manifestation of preeclampsia. Both quantity and quality of maternal-fetal HLA eplet mismatches affects severity of preeclampsia.

Indexed as

Hypertension, Pregnancy-InducedPre-EclampsiaChildFemaleFetusHLA AntigensHLA-B AntigensHLA-C AntigensHumansPregnancyHLA AntigensHLA-B AntigensHLA-C Antigensgestational hypertensionHLA eplet mismatch loadimmunology of pregnancymaternal-fetal HLA compatibilitymaternal-fetal immune tolerancepreeclampsia

Identifiers

PMID38022600
PMCPMC10655094
OpenAlexW4388328054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.